Laboratory of Nanoradiopharmaceuticals and Synthesis of Novel Radiopharmaceuticals, Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro 21941906, Brazil.
Brazilian Biosciences National Laboratory, Brazilian Center for Research in Energy and Materials, Campinas SP13083-970, Brazil.
Curr Med Chem. 2024;31(34):5481-5534. doi: 10.2174/0929867331666230818092634.
Radiopharmaceuticals are increasingly playing a leading role in diagnosing, monitoring, and treating disease. In comparison with conventional pharmaceuticals, the development of radiopharmaceuticals does follow the principles of medicinal chemistry in the context of imaging-altered physiological processes. The design of a novel radiopharmaceutical has several steps similar to conventional drug discovery and some particularity. In the present work, we revisited the insights of medicinal chemistry in the current radiopharmaceutical development giving examples in oncology, neurology, and cardiology. In this regard, we overviewed the literature on radiopharmaceutical development to study overexpressed targets such as prostate-specific membrane antigen and fibroblast activation protein in cancer; β-amyloid plaques and tau protein in brain disorders; and angiotensin II type 1 receptor in cardiac disease. The work addresses concepts in the field of radiopharmacy with a special focus on the potential use of radiopharmaceuticals for nuclear imaging and theranostics.
放射性药物在疾病的诊断、监测和治疗中发挥着越来越重要的作用。与传统药物相比,放射性药物的开发确实遵循了影像学改变生理过程背景下的药物化学原理。新型放射性药物的设计有几个步骤与传统药物发现相似,也有一些特殊性。在本工作中,我们回顾了药物化学在当前放射性药物开发中的见解,并以肿瘤学、神经病学和心脏病学中的例子进行了说明。在这方面,我们综述了放射性药物开发方面的文献,以研究癌症中过表达的靶标,如前列腺特异性膜抗原和成纤维细胞激活蛋白;脑部疾病中的β-淀粉样斑块和tau 蛋白;以及心脏病中的血管紧张素 II 型 1 受体。这项工作涉及放射药学领域的概念,特别关注放射性药物在核成像和治疗中的潜在应用。